Literature DB >> 17652052

Intraperitoneal chemotherapy for optimally debulked advanced ovarian cancer: a new standard in patient care?

A González Martín.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17652052     DOI: 10.1007/s12094-007-0077-5

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  18 in total

1.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

Authors:  Deborah K Armstrong; Brian Bundy; Lari Wenzel; Helen Q Huang; Rebecca Baergen; Shashikant Lele; Larry J Copeland; Joan L Walker; Robert A Burger
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

Review 2.  Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment.

Authors:  Maurie Markman; Joan L Walker
Journal:  J Clin Oncol       Date:  2006-02-06       Impact factor: 44.544

3.  Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

Authors:  D S Alberts; P Y Liu; E V Hannigan; R O'Toole; S D Williams; J A Young; E W Franklin; D L Clarke-Pearson; V K Malviya; B DuBeshter
Journal:  N Engl J Med       Date:  1996-12-26       Impact factor: 91.245

4.  Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.

Authors:  R L Dedrick; C E Myers; P M Bungay; V T DeVita
Journal:  Cancer Treat Rep       Date:  1978-01

5.  Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

Authors:  M J Piccart; K Bertelsen; K James; J Cassidy; C Mangioni; E Simonsen; G Stuart; S Kaye; I Vergote; R Blom; R Grimshaw; R J Atkinson; K D Swenerton; C Trope; M Nardi; J Kaern; S Tumolo; P Timmers; J A Roy; F Lhoas; B Lindvall; M Bacon; A Birt; J E Andersen; B Zee; J Paul; B Baron; S Pecorelli
Journal:  J Natl Cancer Inst       Date:  2000-05-03       Impact factor: 13.506

6.  Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.

Authors:  Lari B Wenzel; Helen Q Huang; Deborah K Armstrong; Joan L Walker; David Cella
Journal:  J Clin Oncol       Date:  2007-02-01       Impact factor: 44.544

7.  2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

Authors:  A du Bois; M Quinn; T Thigpen; J Vermorken; E Avall-Lundqvist; M Bookman; D Bowtell; M Brady; A Casado; A Cervantes; E Eisenhauer; M Friedlaender; K Fujiwara; S Grenman; J P Guastalla; P Harper; T Hogberg; S Kaye; H Kitchener; G Kristensen; R Mannel; W Meier; B Miller; J P Neijt; A Oza; R Ozols; M Parmar; S Pecorelli; J Pfisterer; A Poveda; D Provencher; E Pujade-Lauraine; M Randall; J Rochon; G Rustin; S Sagae; F Stehman; G Stuart; E Trimble; P Vasey; I Vergote; R Verheijen; U Wagner
Journal:  Ann Oncol       Date:  2005       Impact factor: 32.976

8.  Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study.

Authors:  P Francis; E Rowinsky; J Schneider; T Hakes; W Hoskins; M Markman
Journal:  J Clin Oncol       Date:  1995-12       Impact factor: 44.544

9.  Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route.

Authors:  E S Casper; D P Kelsen; N W Alcock; J L Lewis
Journal:  Cancer Treat Rep       Date:  1983-03

10.  Cancer statistics, 2006.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2006 Mar-Apr       Impact factor: 508.702

View more
  3 in total

Review 1.  Epithelial ovarian carcinoma: current evidences and future perspectives in the first-line setting.

Authors:  Antonio González-Martín; Gemma Toledo; Luis Chiva
Journal:  Clin Transl Oncol       Date:  2010-06       Impact factor: 3.405

2.  Anti-angiogenic therapy in ovarian cancer: a great expectation to be confirmed.

Authors:  Antonio González Martín
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

Review 3.  First-line and maintenance therapy for ovarian cancer: current status and future directions.

Authors:  Antonio González-Martín; Luisa Sánchez-Lorenzo; Raquel Bratos; Raúl Márquez; Luis Chiva
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.